Anavex Life Sciences Corp. (NASDAQ:AVXL) Q1 2023 Earnings Call Transcript

Christopher Missling : Exactly, yes. Because the study is large enough that it can carry the signal by itself without AUC.

Yun Zhong : Okay. Great. So the last question, I believe that the original plan is to initiate all those studies that you talked about by year-end last year. And I understand that the focus was on the Alzheimer’s disease program. But are there any specific reason for the delay? Or — also, are you able to provide any specific in terms of timing? When do you expect to initiate those studies?

Christopher Missling : Yeah. So we were very ambitious last year when we made those plans. And the attention to detail required really to finance and work on the specific protocol because it’s easy to start any trial. It’s more difficult to finish a trial successfully, and that’s what we’re aiming for. So I think we should appreciate that initiating a trial is not difficult, it’s about making the trial successful and meaningful for when it’s growing. And so when you look at each trial, there’s always things to consider and you learn to improve it as you go before you really start it. And we didn’t want to rush it. So that’s why we want to say — we want to do this with the right timing. But obviously, we will catch up very nicely now with all these trials, which we plan to do. And they are still on track to be executed.

Yun Zhong : Okay, great. Thank you very much.

Christopher Missling : You’re welcome.

Clint Tomlinson : I don’t see any further questions at this time. Christopher?

Christopher Missling : Good. Thank you. Again, we are very much looking forward and we’re very excited about the company’s potential as we build on biomarker-driven precision medicine studies with significant unmet medical need and economic burden. And we’re looking forward to upcoming data readouts in the Parkinson’s dementia and Alzheimer’s disease with complete data set as well as Parkinson’s dementia open-label extension and the pancreatic Rett syndrome study. Thank you very much.

Clint Tomlinson : All right. Thank you, ladies and gentlemen. This concludes today’s conference. We appreciate you participating. And you may now disconnect.